BioSpace News Archive

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its previously-announced restructuring.

Geneoscopy, Inc. announced that it has petitioned the United States Patent and Trademark Office for inter partes review challenging the patentability of United States Patent No. 11,634,781 owned by Exact Sciences.

Centene Corporation announced today it has completed the previously announced divestiture of Circle Health Group, one of the U.K.'s largest independent operators of hospitals, to Pure Health, the largest integrated healthcare network in the Middle East.

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company focused on the development of Superkines, announced the appointment of MNP LLP as auditor.

Bioventus Inc. announced the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert Claypoole in connection with this appointment as President and Chief Executive Officer, and Principle Executive Officer of the Company.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to one newly hired employee, consisting of inducement stock options to purchase an aggregate of 15,000 shares of common stock and inducement restricted stock units, covering an aggregate of 11,250 shares of its common stock.

Evolus, Inc. reported the grant of non-qualified stock options to purchase an aggregate of 89,770 shares of Evolus and an aggregate of 82,730 restricted stock units of the company’s common stock to six newly hired non-executive employees of the company.

NLS Pharmaceutics Ltd. announced that on January 9, 2024, it received a letter from the Listing Qualifications staff of The Nasdaq Stock Market notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.

Delcath Systems, Inc. announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of two individuals whose employment commenced in December 2023.

Further to Solarvest’s (TSXV: SVS.H) (or “the Company"s) press releases dated May 3, 2023 and July 24, 2023 and to the Exchange’s Notice to transfer to NEX dated September 15, 2023, the Company confirms that the Exchange has issued a bulletin to transfer the Company’s securities to NEX effective at the opening on Tuesday, January 9, 2024.